BASF India Ltd has been downgraded from 'Hold' to 'Sell' by Mojo, due to weakening Return on Equity (ROE), inconsistent capital employed growth, and increased leverage. Investors may want to reconsider their holdings in the company.

BASF India has reported a significant Q4 profit increase of 155%, reaching INR 69 crore, accompanied by a 9.1% revenue growth to INR 3,444 crore. The company also announced a dividend of INR 25 per share and boosted their EBITDA margin to 3.2%. The record date for this dividend is set on July 30, 2026.

BASF India reported a significant 35% year-on-year increase in Q4 net profit, reaching ₹636 million. The company's revenue also grew by 6% YoY, amounting to ₹34 billion in the same quarter.

BASF India proposes a dividend of ₹25 per share for the financial year 2025-26. If approved, shareholders can expect to receive their dividends starting from August 17, 2026.

BASF's Q4 net profit experienced a significant leap of 155%, reaching approximately ₹69 crore, compared to ₹27 crore last year. The company's revenue also increased by 9.1% to around ₹3,444 crore. Notably, EBITDA soared and margins doubled, improving from 1.6% to 3.2%.

BASF, a leading chemical company, has seen a 19.5% increase in stock value this year. The company aims to expand its reach into pharmaceuticals and enhance supply chain efficiency by utilizing advanced technology and regulatory knowledge. Investors closely watch partnerships, acquisitions, and the role of fine chemicals in driving high-margin growth for BASF.

BASF India's outlook has been revised to 'Hold', reflecting improved valuation factors such as P/E and P/BV ratios, suggesting a potentially better investment opportunity amidst market difficulties.

BASF India is set to sell its coatings division, BASF India Coatings Pvt Ltd, to the Carlyle Group for approximately INR 230 crore. The deal, expected to close in Q2 of 2026, represents a 3.1% contribution to revenue in FY25 for BASF India.

BASF Pharma Solutions has announced a global increase in prices for APIs (Active Pharmaceutical Ingredients) and excipients. This move is intended to ensure the reliability and quality of their product offerings.